Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Eli Lilly reports positive data from atopic dermatitis trials

Baricitinibis approved for use in the treatment of adults with moderately to severely active rheumatoid arthritis. Credit: Photo by Thought Catalog on Unsplash.

  • Eli Lilly

Go Top